HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation

被引:188
作者
Krampera, M
Pasini, A
Rigo, A
Scupoli, MT
Tecchio, C
Malpeli, G
Scarpa, A
Dazzi, F
Pizzolo, G
Vinante, F
机构
[1] Univ Verona, Policlin GB Rossi, Sect Haematol, Dept Clin & Expt Med, I-37134 Verona, Italy
[2] Univ Verona, Sect Pathol Anat, Dept Pathol, I-37134 Verona, Italy
[3] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Dept Immunol, London SW7 2AZ, England
关键词
D O I
10.1182/blood-2004-09-3645
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Epidermal growth factor receptor-1 (EGFR-1/ HER-1/ErbB-1) regulates proliferation and cell fate during epidermal development. HER-1 is activated by several EGF-family ligands including heparin-binding epidermal growth factor-like growth factor (HB-EGF), a mitogenic and chemotactic molecule that participates in tissue repair, tumor growth, and other tissue-modeling phenomena, such as angiogenesis and fibrogenesis. We found that mesenchymal stem cells (MSCS), the precursors of different mesenchymal tissues with a role in processes in which HB-EGF is often involved, normally express HEIR-1, but not HB-EGF itself. Under the effect of HB-EGF, MSCs proliferate more rapidly and persistently, without undergoing spontaneous differentiation. This effect occurs in a dose-dependent fashion, and is specific, direct, and HER-1 mediated, as it is inhibited by anti-HEIR-1 and anti-HB-EGF blocking antibodies. Moreover, HB-EGF reversibly prevents adipogenic, osteogenic, and chondrogenic differentiation induced with specific media. These data show that HB-EGF/HER-1 signaling is relevant to MSC biology, by regulating both proliferation and differentiation.
引用
收藏
页码:59 / 66
页数:8
相关论文
共 40 条
[1]   Intercellular communication between vascular smooth muscle and endothelial cells mediated by heparin-binding epidermal growth factor-like growth factor and vascular endothelial growth factor [J].
Abramovitch, R ;
Neeman, M ;
Reich, R ;
Stein, I ;
Keshet, E ;
Abraham, J ;
Solomon, A ;
Marikovsky, M .
FEBS LETTERS, 1998, 425 (03) :441-447
[2]   The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions [J].
Alroy, I ;
Yarden, Y .
FEBS LETTERS, 1997, 410 (01) :83-86
[3]   Targeting HERI/EGFR: A molecular approach to cancer therapy [J].
Arteaga, C .
SEMINARS IN ONCOLOGY, 2003, 30 (03) :3-14
[4]   Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy [J].
Asakura, M ;
Kitakaze, M ;
Takashima, S ;
Liao, Y ;
Ishikura, F ;
Yoshinaka, T ;
Ohmoto, H ;
Node, K ;
Yoshino, K ;
Ishiguro, H ;
Asanuma, H ;
Sanada, S ;
Matsumura, Y ;
Takeda, H ;
Beppu, S ;
Tada, M ;
Hori, M ;
Higashiyama, S .
NATURE MEDICINE, 2002, 8 (01) :35-40
[5]  
CHAPEKAR MS, 1988, MOL PHARMACOL, V34, P461
[6]  
CMOGORACJURCEVI.T, 2002, ONCOGENE, V21, P4587
[7]  
DAS SK, 1994, DEVELOPMENT, V120, P1071
[8]  
DLUZ SM, 1993, J BIOL CHEM, V268, P18330
[9]   Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation [J].
Elenius, K ;
Paul, S ;
Allison, G ;
Sun, J ;
Klagsbrun, M .
EMBO JOURNAL, 1997, 16 (06) :1268-1278
[10]   Involvement of wound-associated factors in rat brain astrocyte migratory response to axonal injury: In vitro simulation [J].
FaberElman, A ;
Solomon, A ;
Abraham, JA ;
Marikovsky, M ;
Schwartz, M .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (01) :162-171